Jason D. Weber, Ph.D.

Internal Medicine
Molecular Oncology
Cell Biology and Physiology

Cancer Biology Program
Molecular Cell Biology Program
Molecular Genetics and Genomics Program

  • 314-747-3896

  • 314-747-3898

  • 314-747-2797

  • ICCE Institute, BJC-IH Building, 7th Floor, Room 7307

  • jweber@wustl.edu

  • http://www.icce-wustl.org/jason-weber-lab.html

  • Breast cancer, lung cancer, tumor suppressors, oncogenes, microfluidics, RNA editing, metastasis

  • Tumor suppressor and oncogene networks in cancer biology

Research Abstract:

The goal of the lab is to understand how tumor suppressors and oncogenes functionally interact to determine the fate of cells. Ongoing projects are diverse in approaches and translational impact. Members of the lab often translate their findings into clinical setting through ongoing collaborations with oncology physicians.

Specific Projects:
1. The collaboration of the ARF and p53 tumor suppressors in preventing breast cancer.
2. Restoration of ARF tumor suppressor function through peptide mimics.
3. Functional interaction of ADAR1 and MDM2 oncogenes in ferroptosis.
4. Collaborative regulation of translational targets by the ARF and NF1 tumor suppressors.
5. Targeting an innate immune signaling pathway in breast cancer.
6. Identifying drivers of triple-negative breast cancer in African American women.
7. Using high-throughput DNA-barcoded chemical libraries to screen for oncogene inhibitors.
8. Design and fabrication of novel microfluidic devices to model lymphatics in breast cancer metastasis.

Mentorship and Commitment to Diversity Statement:
I have trained 16 PhD graduate students, 2 MSTP students, 12 postdoctoral researchers, and 39 undergraduate research students, 12 of which were underrepresented minorities in my 20 years at Washington University. I am also the head of the new American Cancer Society Diversity Internship in Cancer Research Program that provides summer research opportunities to underrepresented Washington University undergrads.

Selected Publications:

Kung C.P. and Weber J.D. (2022). href="https://www.frontiersin.org/articles/10.3389/fcell.2022.818744/full">It’s getting complicated-a fresh look at p53-Mdm2-ARF triangle in tumorigenesis and cancer therapy. Frontiers in Cell and Developmental Biology, 10:1-26.

Cottrell K.A., Soto Torres, L., Dizon M.G and Weber J.D. (2021). href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113518/">8-azaadenosine and 8-chloroadenosine are not selective inhibitors of ADAR. Cancer Research Communications, 2:56-64.

Cho B., Han Y., Lian M., Colditz G.A., Weber J.D., Ma C. and Liu Y. (2021). href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2780032">Evaluation of racial/ethnic differences in treatment and mortality among women with triple-negative breast cancer. JAMA Oncology, 7:1016-1023.

Kung C.P., Cottrell K.A., Ryu S., Bramel E.R., Kladney R.D., Bross E.A., Maggi L.B. and Weber J.D. (2021). Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer. Oncogene, 40:189-202.

Cottrell K.A., Chiou R.C. and Weber J.D. (2020). ARF suppresses 5’-terminal oligopyrimidine mRNA translation. Scientific Reports, i10:22276-89.

Dania V., Liu Y., Ademuyiwa F., Weber J.D., and Colditz G.A. (2019). Associations of race and ethnicity with risk of developing invasive breast cancer after lobular carcinoma in situ. Breast Cancer Research, 21:120-6.

Liu Y., West R., Weber J.D., and Colditz G.A. (2019). Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ. Cancer, 125:3225-3233.

Wang J. Yuan Z., Weber J.D., and Zhang Y. (2019). DHX33 interacts with AP-2b to regulate gene expression and promote cancer cell survival. Molecular and Cellular Biology, 39:1-20

Last Updated: 7/25/2022 4:38:51 PM

Back To Top

Follow us: